Comparative Pharmacology
Head-to-head clinical analysis: TRIAVIL 2 25 versus TRIAVIL 4 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIAVIL 2 25 versus TRIAVIL 4 10.
TRIAVIL 2-25 vs TRIAVIL 4-10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TRIAVIL 2-25 contains perphenazine and amitriptyline. Perphenazine is a typical antipsychotic that blocks postsynaptic dopamine D2 receptors in the brain, reducing dopaminergic neurotransmission. It also has alpha-adrenergic and anticholinergic effects. Amitriptyline is a tricyclic antidepressant that inhibits the reuptake of serotonin and norepinephrine, increasing their levels in the synaptic cleft. It also blocks histamine H1, muscarinic, and alpha-adrenergic receptors.
TRIAVIL 4-10 contains perphenazine, a typical antipsychotic that blocks postsynaptic dopamine D1 and D2 receptors in the limbic system, basal ganglia, and hypothalamus, and amitriptyline, a tricyclic antidepressant that inhibits serotonin and norepinephrine reuptake.
One tablet (2 mg perphenazine / 25 mg amitriptyline) orally 3 to 4 times daily; maintenance dose: 2 to 4 tablets daily.
1 tablet (perphenazine 4 mg / amitriptyline 10 mg) orally 3 times daily, maximum 8 tablets daily.
None Documented
None Documented
Amitriptyline: 9-25 hours (mean 15 hours); perphenazine: 9-12 hours. Steady-state achieved in 3-7 days.
Amitriptyline: 10-28 hours (mean 21 hours); perphenazine: 8-12 hours (mean 10 hours). Clinically, steady-state achieved in 3-5 days for amitriptyline, 2-3 days for perphenazine.
Primarily renal (approximately 70-80% as metabolites, <5% unchanged for amitriptyline; perphenazine excreted renally and fecally).
Primarily renal (about 50-70% as metabolites, <5% unchanged) and fecal (30-50% via biliary elimination).
Category C
Category C
Antidepressant-Antipsychotic Combination
Antidepressant-Antipsychotic Combination